| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 1/6 |
| Financial Health | 3/6 |
| Dividends | 0/6 |
KOREA PHARMA Co., Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | ₩19,320.00 |
| 52 Week High | ₩29,450.00 |
| 52 Week Low | ₩15,020.00 |
| Beta | 1.35 |
| 1 Month Change | -4.12% |
| 3 Month Change | -12.78% |
| 1 Year Change | -3.40% |
| 3 Year Change | -62.85% |
| 5 Year Change | n/a |
| Change since IPO | 14.66% |
Recent News & Updates
Shareholder Returns
| A032300 | KR Pharmaceuticals | KR Market | |
|---|---|---|---|
| 7D | 0.1% | 1.2% | 1.8% |
| 1Y | -3.4% | 10.0% | 9.5% |
Return vs Industry: A032300 underperformed the KR Pharmaceuticals industry which returned 10% over the past year.
Return vs Market: A032300 underperformed the KR Market which returned 9.5% over the past year.
Price Volatility
| A032300 volatility | |
|---|---|
| A032300 Average Weekly Movement | 4.6% |
| Pharmaceuticals Industry Average Movement | 4.5% |
| Market Average Movement | 5.0% |
| 10% most volatile stocks in KR Market | 11.6% |
| 10% least volatile stocks in KR Market | 2.3% |
Stable Share Price: A032300 has not had significant price volatility in the past 3 months.
Volatility Over Time: A032300's weekly volatility (5%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1974 | n/a | n/a | www.koreapharma.co.kr |
KOREA PHARMA Co., Ltd. . produces pharmaceutical drugs. The company offers amino acid, antibiotic, antidotal, antiepileptic, antihistamine, anti-inflammatory, antimicrobial, antiplatelet, circulatory system, CNS, dermatological, endocrine, gastrointestinal, hepatic, hormonal, respiratory, sympathomimetic, skeltal muscle relaxants, and specialty drugs, as well as multivitamins, and vitamin B1, etc. KOREA PHARMA Co., Ltd.
KOREA PHARMA Co., Ltd. Fundamentals Summary
| A032300 fundamental statistics | |
|---|---|
| Market cap | ₩210.72b |
| Earnings (TTM) | ₩83.76m |
| Revenue (TTM) | ₩83.24b |
2,516x
P/E Ratio2.5x
P/S RatioIs A032300 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| A032300 income statement (TTM) | |
|---|---|
| Revenue | ₩83.24b |
| Cost of Revenue | ₩46.34b |
| Gross Profit | ₩36.90b |
| Other Expenses | ₩36.82b |
| Earnings | ₩83.76m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | 7.68 |
| Gross Margin | 44.33% |
| Net Profit Margin | 0.10% |
| Debt/Equity Ratio | 49.6% |
How did A032300 perform over the long term?
See historical performance and comparison